Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs and Disease Flare in Patients With Rheumatoid Arthritis—Reply

Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs and Disease... Letters Gao and colleagues suggest that we “consider hearing and The rate of arthritis flare in the half-dose group was greater vision levels” in the study “to avoid these possible confound- than in the continuation group (25% vs 6%), leading the au- ing factors.” Sensory impairment would need to be the cause thors to conclude that their findings “do not support treat- of both early-onset diabetes and dementia to be a con- ment with half-dose therapy.” However, as discussed in the ac- founder. There is no evidence that sensory impairment causes companying Editorial, 75% of patients in the half-dose group early-onset diabetes. While both sensory impairment and de- maintained remission. Furthermore, RA flares were gener- mentia increase exponentially with age, the nature of their re- ally mild and rapidly controlled, and disease activity did not lationship requires further investigation. differ between groups at 12 months. The Editorial suggested Second, Gao and colleagues suggest that metformin use these results may “guide discussions of dose reductions for pa- may be associated with lower risk of incident dementia com- tients who have adverse drug effects or who have other rea- pared with sulfonylurea drugs. Our study was not set up to sons http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs and Disease Flare in Patients With Rheumatoid Arthritis—Reply

Loading next page...
 
/lp/american-medical-association/half-dose-vs-stable-dose-conventional-synthetic-disease-modifying-OBRoKWJUX7
Publisher
American Medical Association
Copyright
Copyright 2021 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2021.10651
Publisher site
See Article on Publisher Site

Abstract

Letters Gao and colleagues suggest that we “consider hearing and The rate of arthritis flare in the half-dose group was greater vision levels” in the study “to avoid these possible confound- than in the continuation group (25% vs 6%), leading the au- ing factors.” Sensory impairment would need to be the cause thors to conclude that their findings “do not support treat- of both early-onset diabetes and dementia to be a con- ment with half-dose therapy.” However, as discussed in the ac- founder. There is no evidence that sensory impairment causes companying Editorial, 75% of patients in the half-dose group early-onset diabetes. While both sensory impairment and de- maintained remission. Furthermore, RA flares were gener- mentia increase exponentially with age, the nature of their re- ally mild and rapidly controlled, and disease activity did not lationship requires further investigation. differ between groups at 12 months. The Editorial suggested Second, Gao and colleagues suggest that metformin use these results may “guide discussions of dose reductions for pa- may be associated with lower risk of incident dementia com- tients who have adverse drug effects or who have other rea- pared with sulfonylurea drugs. Our study was not set up to sons

Journal

JAMAAmerican Medical Association

Published: Sep 7, 2021

References